✦ LIBER ✦

Risperidone augmentation in refractory obsessive compulsive disorder: An open-label study

✍ Scribed by C. Pfanner; D. Marazziti; L. Dell'Osso; S. Presta; A. Gemignani; A. Milanfranchi; G.B. Cassano

Book ID: 119574892
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 260 KB
Volume: 10
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(00)80450-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Olanzapine augmentation in refractory ob

Olanzapine augmentation in refractory obsessive compulsive disorder: An open-label study

✍ G. Corretti; M. Abelli; C. Pfanner; A. Gemignani; A. Ciapparelli; D. Marazziti; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Riluzole Augmentation in Treatment-Resis

Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial

✍ Vladimir Coric; Sarper Taskiran; Christopher Pittenger; Suzanne Wasylink; Daniel 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Open-label pilot study of tramadol hydro

Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder

✍ Nathan A. Shapira; Paul E. Keck Jr.; Toby D. Goldsmith; Brian J. McConville; Mic 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB 👁 2 views

Open-label olanzapine in obsessive-compu

Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment

✍ M.A. Crocq; Ph. Leclercq; M.S. Guillon; P.E. Bailey 📂 Article 📅 2002 🏛 Elsevier Science 🌐 French ⚖ 51 KB

Aripiprazole augmentation in treatment-r

Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder

✍ Rahul Sarkar; Julia Klein; Stephanie Krüger 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 57 KB

Amisulpiride augmentation in treatment r

Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial

✍ Özmen Metin; Kemal Yazici; Senel Tot; Aylin Ertekin Yazici 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsyc